Immunoadsorption in Autoimmune Long COVID
Recruiting
Phase 2
Interventional Study
Long COVID
Long COVID Syndrome
Long COVID-19 Syndrome
Post COVID Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 70 (estimated)
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.
This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly as…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Long COVID based on the WHO-criteria
* PEM according to the DSQ-PEM
* BELL's functionality score 20-70%
* Good health prior to the long COVID diagnosis (WHO performance score 0)
Exclusion Criteria:
* Medical history of clinically significant respiratory- or cardiovascular di…
Contacts